v2.4.0.6
Quarterly Results Of Operations (Schedule Of Quarterly Results Of Operations) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 12 Months Ended
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2010
Sep. 30, 2010
Jun. 30, 2010
Mar. 31, 2010
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Quarterly Results Of Operations [Abstract]                      
Total revenues $ 2,200,378 [1] $ 2,121,660 [1] $ 2,137,253 [1] $ 1,926,094 [1] $ 1,998,687 [2] $ 1,937,656 [2] $ 1,927,224 [2] $ 2,085,853 [2] $ 8,385,385 $ 7,949,420 $ 7,011,383
Gross profit on product sales 1,548,887 [1] 1,533,870 [1] 1,505,725 [1] 1,389,467 [1] 1,433,901 [2] 1,387,975 [2] 1,350,536 [2] 1,347,633 [2]      
Net income 661,759 [1] 737,538 [1] 742,459 [1] 647,303 [1] 626,365 [2] 702,163 [2] 709,127 [2] 852,094 [2] 2,789,059 2,889,749 2,625,592
Net income attributable to Gilead 665,145 [1] 741,124 [1] 746,227 [1] 651,141 [1] 629,419 [2] 704,876 [2] 712,061 [2] 854,901 [2] 2,803,637 2,901,257 2,635,755
Net income per share attributable to Gilead common stockholders-basic $ 0.88 [1] $ 0.97 [1] $ 0.95 [1] $ 0.82 [1] $ 0.78 [2] $ 0.85 [2] $ 0.81 [2] $ 0.95 [2] $ 3.62 $ 3.39 $ 2.91
Net income per share attributable to Gilead common stockholders-diluted $ 0.87 [1] $ 0.95 [1] $ 0.93 [1] $ 0.80 [1] $ 0.76 [2] $ 0.83 [2] $ 0.79 [2] $ 0.92 [2] $ 3.55 $ 3.32 $ 2.82
In-process research and development impairment charges $ 26,600       $ 136,000       $ 26,630 $ 136,000 $ 0
[1] During the fourth quarter of 2011, we recorded $26.6 million of impairment charges in R&D expense, related to certain IPR&D assets acquired from CGI. See Notes 5 and 9.
[2] During the fourth quarter of 2010, we recorded $136.0 million of impairment charges in R&D expense, related to certain IPR&D assets acquired from CV Therapeutics. See Notes 5 and 9.